Quarterly report · Q3
3341.TEDINET S100Q7DI
Period2022-04-01 → 2022-12-31
Filed2023-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥232.8bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥299.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥223.4bn | 2021-04-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | ¥5.8bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | ¥5.8bn | 2021-04-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | ¥5.8bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥6.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.1bn | 2021-04-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥7.0bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.0bn | 2021-04-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.3bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.7bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.1bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥4.3bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | ¥1.1bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥187.6bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥178.8bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥181.9bn | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥131.3bn | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥125.9bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥56.3bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥52.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥50.2bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥20.3bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥25.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥143.23 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥89.64 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.56 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥36.57 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-8.14 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 30.0% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.6% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 37
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥10.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥10.5bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥4.9bn |
| jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥208.1bn |
| jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥208.1bn |
| jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥2m |
| jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥10.6bn |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥5.9bn |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥5.9bn |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥10m |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥602m |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥29.3bn |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥18.9bn |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥10.4bn |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | −¥456m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥243.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥232.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥10.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥10.7bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-12-31 | −¥14.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-12-31 | −¥14.4bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-12-31 | −¥5.0bn |
| jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥197.4bn |
| jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥197.4bn |
| jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥9.1bn |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥5.2bn |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥5.2bn |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥6m |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥423m |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥35.3bn |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥20.8bn |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥14.4bn |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥1.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-12-31 | ¥237.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-12-31 | ¥223.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥14.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-12-31 | ¥10.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 364
| Item | Context | Value | Unit |
|---|---|---|---|
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |